OBI Pharma (ROCO:4174) ROCE % : -43.54% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OBI Pharma's annualized ROCE % for the quarter that ended in Mar. 2024 was -43.54%.

OBI Pharma ROCE % Historical Data

The historical data trend for OBI Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma ROCE % Chart

OBI Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-31.54

-26.20

-37.58

-36.19

-21.38

OBI Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-25.78	20.84	-40.51	-39.12	-43.54

OBI Pharma ROCE % Calculation

OBI Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1267.617	/	( ( (6633.701 - 221.138)	+	(5603.89 - 158.618) )	/ 2 )
	=	-1267.617	/	( (6412.563	+	5445.272)	/ 2 )
	=	-1267.617	/	5928.9175
	=	-21.38 %

OBI Pharma's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-2250.992	/	( ( (5603.89 - 158.618)	+	(5035.251 - 141.231) )	/ 2 )
	=	-2250.992	/	( ( 5445.272	+	4894.02 )	/ 2 )
	=	-2250.992	/	5169.646
	=	-43.54 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

OBI Pharma (ROCO:4174) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OBI Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of OBI Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OBI Pharma (ROCO:4174) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3, Park Street, Room. 1907, 19th Floor, Nangang District, Taipei, TWN, 115

Website

https://www.obipharma.com

OBI Pharma Inc is part of the healthcare sector. The company and its subsidiaries are engaged in new drug research. Its focus is on the unmet medical need in challenging diseases throughout the world, such as cancer. OBI strives to improve health and the quality of life through cost-effective therapeutics. The Group has four reportable segments, which are the anti-cancer new drug segment, bispecific monoclonal antibody new drug segment, botulinum toxin new drug segment, and CDMO segment.

OBI Pharma (ROCO:4174) Headlines

No Headlines